Cargando…

Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments

BACKGROUND: Pancreatic cancer is one of the most lethal cancers worldwide. Aidi injection (ADI) is a representative antitumor medication based on Chinese herbal injection, but its antitumor mechanisms are still poorly understood. MATERIALS AND METHODS: In this work, the subcutaneous xenograft model...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haojia, Wu, Zhishan, Fan, Xiaotian, Wu, Chao, Lu, Shan, Geng, Libo, Stalin, Antony, Zhu, Yingli, Zhang, Fanqin, Huang, Jiaqi, Liu, Pengyun, Li, Huiying, You, Leiming, Wu, Jiarui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840244/
https://www.ncbi.nlm.nih.gov/pubmed/36641437
http://dx.doi.org/10.1186/s13020-023-00710-2
_version_ 1784869601058750464
author Wang, Haojia
Wu, Zhishan
Fan, Xiaotian
Wu, Chao
Lu, Shan
Geng, Libo
Stalin, Antony
Zhu, Yingli
Zhang, Fanqin
Huang, Jiaqi
Liu, Pengyun
Li, Huiying
You, Leiming
Wu, Jiarui
author_facet Wang, Haojia
Wu, Zhishan
Fan, Xiaotian
Wu, Chao
Lu, Shan
Geng, Libo
Stalin, Antony
Zhu, Yingli
Zhang, Fanqin
Huang, Jiaqi
Liu, Pengyun
Li, Huiying
You, Leiming
Wu, Jiarui
author_sort Wang, Haojia
collection PubMed
description BACKGROUND: Pancreatic cancer is one of the most lethal cancers worldwide. Aidi injection (ADI) is a representative antitumor medication based on Chinese herbal injection, but its antitumor mechanisms are still poorly understood. MATERIALS AND METHODS: In this work, the subcutaneous xenograft model of human pancreatic cancer cell line Panc-1 was established in nude mice to investigate the anticancer effect of ADI in vivo. We then determined the components of ADI using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) and explored the possible molecular mechanisms against pancreatic cancer using network pharmacology. RESULTS: In vivo experiments, the volume, weight, and degree of histological abnormalities of implanted tumors were significantly lower in the medium and high concentration ADI injection groups than in the control group. Network pharmacology analysis identified four active components of ADI and seven key targets, TNF, VEGFA, HSP90AA1, MAPK14, CASP3, P53 and JUN. Molecular docking also revealed high affinity between the active components and the target proteins, including Astragaloside IV to P53 and VEGFA, Ginsenoside Rb1 to CASP3 and Formononetin to JUN. CONCLUSION: ADI could reduce the growth rate of tumor tissue and alleviate the structural abnormalities in tumor tissue. ADI is predicted to act on VEGFA, P53, CASP3, and JUN in ADI-mediated treatment of pancreatic cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00710-2.
format Online
Article
Text
id pubmed-9840244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98402442023-01-15 Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments Wang, Haojia Wu, Zhishan Fan, Xiaotian Wu, Chao Lu, Shan Geng, Libo Stalin, Antony Zhu, Yingli Zhang, Fanqin Huang, Jiaqi Liu, Pengyun Li, Huiying You, Leiming Wu, Jiarui Chin Med Research BACKGROUND: Pancreatic cancer is one of the most lethal cancers worldwide. Aidi injection (ADI) is a representative antitumor medication based on Chinese herbal injection, but its antitumor mechanisms are still poorly understood. MATERIALS AND METHODS: In this work, the subcutaneous xenograft model of human pancreatic cancer cell line Panc-1 was established in nude mice to investigate the anticancer effect of ADI in vivo. We then determined the components of ADI using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) and explored the possible molecular mechanisms against pancreatic cancer using network pharmacology. RESULTS: In vivo experiments, the volume, weight, and degree of histological abnormalities of implanted tumors were significantly lower in the medium and high concentration ADI injection groups than in the control group. Network pharmacology analysis identified four active components of ADI and seven key targets, TNF, VEGFA, HSP90AA1, MAPK14, CASP3, P53 and JUN. Molecular docking also revealed high affinity between the active components and the target proteins, including Astragaloside IV to P53 and VEGFA, Ginsenoside Rb1 to CASP3 and Formononetin to JUN. CONCLUSION: ADI could reduce the growth rate of tumor tissue and alleviate the structural abnormalities in tumor tissue. ADI is predicted to act on VEGFA, P53, CASP3, and JUN in ADI-mediated treatment of pancreatic cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00710-2. BioMed Central 2023-01-14 /pmc/articles/PMC9840244/ /pubmed/36641437 http://dx.doi.org/10.1186/s13020-023-00710-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Haojia
Wu, Zhishan
Fan, Xiaotian
Wu, Chao
Lu, Shan
Geng, Libo
Stalin, Antony
Zhu, Yingli
Zhang, Fanqin
Huang, Jiaqi
Liu, Pengyun
Li, Huiying
You, Leiming
Wu, Jiarui
Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments
title Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments
title_full Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments
title_fullStr Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments
title_full_unstemmed Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments
title_short Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments
title_sort identification of key pharmacological components and targets for aidi injection in the treatment of pancreatic cancer by uplc-ms, network pharmacology, and in vivo experiments
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840244/
https://www.ncbi.nlm.nih.gov/pubmed/36641437
http://dx.doi.org/10.1186/s13020-023-00710-2
work_keys_str_mv AT wanghaojia identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT wuzhishan identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT fanxiaotian identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT wuchao identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT lushan identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT genglibo identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT stalinantony identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT zhuyingli identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT zhangfanqin identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT huangjiaqi identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT liupengyun identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT lihuiying identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT youleiming identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments
AT wujiarui identificationofkeypharmacologicalcomponentsandtargetsforaidiinjectioninthetreatmentofpancreaticcancerbyuplcmsnetworkpharmacologyandinvivoexperiments